Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BX63
UPID:
FANCJ_HUMAN
Alternative names:
ATP-dependent RNA helicase BRIP1; BRCA1-associated C-terminal helicase 1; BRCA1-interacting protein C-terminal helicase 1
Alternative UPACC:
Q9BX63; A0A024QZ45; Q3MJE2; Q8NCI5
Background:
The Fanconi anemia group J protein, also known as ATP-dependent RNA helicase BRIP1, BRCA1-associated C-terminal helicase 1, and BRCA1-interacting protein C-terminal helicase 1, plays a crucial role in maintaining chromosomal stability. It functions as a DNA-dependent ATPase and 5' to 3' DNA helicase, pivotal in the repair of DNA double-strand breaks through homologous recombination, particularly in association with BRCA1.
Therapeutic significance:
This protein's involvement in breast cancer and Fanconi anemia complementation group J underscores its therapeutic significance. Its role in DNA repair mechanisms and chromosomal stability presents a promising target for developing treatments for these conditions, highlighting the potential for novel therapeutic strategies aimed at modulating its activity.